Melanoma News and Research RSS Feed - Melanoma News and Research

Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
Anti-TNF therapy linked to ‘modest’ extra SCC risk

Anti-TNF therapy linked to ‘modest’ extra SCC risk

A Swedish population-based study shows that treatment with tumour necrosis factor inhibitors significantly increases the risk of developing squamous cell carcinoma, but not basal cell carcinoma, in patients with rheumatoid arthritis. [More]
New research identifies key enzyme linked to age-related increases in cancer and inflammation

New research identifies key enzyme linked to age-related increases in cancer and inflammation

For the first time, researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
NJHF awards 30 grants for NJ researchers working on health-related research

NJHF awards 30 grants for NJ researchers working on health-related research

New Jersey Health Foundation has awarded 30 grants totaling more than $1 million for researchers in New Jersey who are working on health-related research that demonstrates exciting potential. [More]
Height affects risk of major non-communicable diseases

Height affects risk of major non-communicable diseases

Height is largely genetically determined, but in recent decades the height of children and adults has steadily increased throughout the world: In adulthood the children are almost always significantly taller than their parents. [More]
New drug cocktail may show promise in NSCLC patients

New drug cocktail may show promise in NSCLC patients

A drug approved by the Food and Drug Administration for melanoma in combination with a common cholesterol-lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai. [More]
Biochemical compound demonstrates increasing potential for use in cancer imaging

Biochemical compound demonstrates increasing potential for use in cancer imaging

In the paper, an international team reviewed studies conducted over the past 30 years on a particular tracer, called “18F-FLT,” and found that it has the potential to improve diagnostic imaging, and thus treatment, of some cancers. [More]
Rockland announces availability of new human melanoma cell lines

Rockland announces availability of new human melanoma cell lines

Rockland Immunochemicals, Inc. announces the availability of a new collection of human melanoma cell lines that have been developed and characterized over several decades in the laboratory of Meenhard Herlyn, D.V.M., D.Sc., Caspar Wistar Professor in Melanoma Research, Director of the Melanoma Research Center, and professor in the Molecular and Cellular Oncogenesis Program at The Wistar Institute in Philadelphia. [More]
Access for new melanoma treatment remains uncertain for patients despite UK launch

Access for new melanoma treatment remains uncertain for patients despite UK launch

Novartis announced today that Tafinlar (dabrafenib) + Mekinist (trametinib), the first oral combination therapy to be licensed for advanced melanoma, is now available in the UK for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. [More]
Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center. [More]
Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

While there are a range of reports that different foods and food groups can increase or decrease your risk of cancer, these associations are very difficult to scientifically verify. [More]
FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. [More]
Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company. [More]
AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

AVAX Technologies, Inc., a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer. [More]
MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer. [More]
Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach. [More]
Study provides evidence for use of inherited genetic markers to improve melanoma prognostication

Study provides evidence for use of inherited genetic markers to improve melanoma prognostication

Melanoma is the most dangerous and lethal form of skin cancer. But just how long will a patient survive following the removal of a melanoma tumor? A more definitive answer to that question could come from new studies at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. Researchers there have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual's survival and determine which patients require closer monitoring in the years following surgery. [More]
Experts create new guidelines to improve treatments for cancer patients

Experts create new guidelines to improve treatments for cancer patients

A committee of national experts, led by a Cleveland Clinic researcher, has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes. [More]
WASF3 protein appears to be solid target for reducing cancer metastasis

WASF3 protein appears to be solid target for reducing cancer metastasis

A protein that is constantly expressed by cancer cells and quiescent in healthy ones appears to be a solid target for reducing cancer's ability to spread, scientists report. [More]
Physicians may soon have new tool to closely track severity, potential spread of metastatic melanoma

Physicians may soon have new tool to closely track severity, potential spread of metastatic melanoma

Physicians treating patients with metastatic melanoma — one of the most aggressive forms of skin cancer — may soon have a superior tool in their efforts to closely track the disease. [More]
Wistar Institute scientists use revolutionary method to block melanoma progression

Wistar Institute scientists use revolutionary method to block melanoma progression

Melanoma patients who receive treatment with targeted therapies experience an initial response that feels like a cure, but that early excitement is quickly dampened when patients relapse as their cancers find alternative pathways in our cells to grow and spread. With melanoma so good at escaping targeted treatments, there's a dire need to halt these cancers in their tracks to prolong good responses and promote longer, healthier lives. [More]
Advertisement